#### South Carolina

# **Department of Health and Human Services**

Post Office Box 8206 Columbia, South Carolina 29202-8206

# Pharmacy and Therapeutics (P&T) Committee Meeting May 4, 2016 MINUTES

## 1. Call to Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, May 4, 2016.

## 2. Welcome

Edward Behling, MD, called the meeting to order and welcomed members, guests, and staff members.

Dr. Behling opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

## 3. Committee Members Present:

Kelly Jones, PharmD Tan Platt, MD Cheryl Hartvigsen, R.Ph.
Philip Mubarak, MD Edward Behling, MD

**SC DHHS Staff:** 

Bryan Amick, PharmD, MBA Jim Bradford, MD Janet Giles Constance Holloway, JD **Magellan Medicaid Admin:** 

Lisa Correll, PharmD Lori Ash

## 4. Discussion Topics

## A. Committee Meeting Minutes, Wednesday, February 3, 2016

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

# **B.** Public Comment

Company	Speaker	Drug/Class
Mylan, Inc	John Howard, PharmD Epinephrine (Inj)	

# C. <u>Drug Classes for Review</u>

Lisa Correll led the discussion for the following drug classes:

Classes for Re-Review

Otic Antibiotics

Antibiotics, Topical

Antivirals, Topical

Hypoglycemics, Metformin

Acne Agents, Topical (Retinoids)

Acne Agents, Topical (Sodium Sulfacetamide/Sulfur)

Epinephrine, Injectable

Classes for Review

**Emergency Treatment: Opioid Overdose** 

The chart below represents the recommendations from the P & T Committee:

OTIC ANTIBIOTICS	
Preferred	Non-Preferred
Ciprodex <sup>®</sup>	Cipro HC®
	Ciprofloxacin
	Ofloxacin

ANTIBIOTICS, TOPICAL	
Preferred	Non-Preferred
Mupirocin Ointment	Altabax <sup>®</sup>
	Bactroban® Cream/Ointment
	Centany/Centany AT Kit
	Mupirocin Cream

ANTIVIRALS, TOPICAL	
Preferred	Non-Preferred
Abreva	Acyclovir Ointment
Zovirax Cream	Denavir
	Xerese
	Zovirax Ointment

HYPOGLYCEMICS, METFORMIN	
Preferred	Non-Preferred
Metformin	Fortamet <sup>®</sup>
Metformin ER	Glucophage/Glucophage XR
	Glumetza <sup>®</sup>
	Riomet® (suspension)

ACNE AGENTS, TOPICAL (RETINOIDS)	
Preferred	Non-Preferred
Retin A gel/cream	Atralin <sup>®</sup> gel
	Avita® gel
	Retin-A Micro®/pump
	Tretin-X <sup>®</sup> gel/cream
	Tretinoin
	Veltin® gel
	Ziana® gel
	Tazorac <sup>®</sup> / Fabior <sup>®</sup>

ACNE AGENTS, TOPICAL (SODIUM SULFACETAMIDE/SULFUR)	
Preferred	Non-Preferred
	Klaron
	Ovace/Ovace Plus
	Avar
	Clarifoam
	Claris
	Plexion
	Rosanil
	Rosula
	Sumadan
	Sumaxin
	Zencia
	Generic Sodium Sulfacetamide / Sulfur
	Preparations

EPINEPHRINE (INJECTABLES)		
Preferred	Non-Preferred	
EPIPEN® / EPIPEN JR®		
Adrenaclick/generic (autoinjector)		

EMERGENCY TREATMENT: OPIOID OVERDOSE		
Preferred	Non-Preferred	
Narcan Nasal Spray	Evzio	
Naloxone Vial/Syringe		

#### 5. Old Business

None

## 6. New Business

Bryan addressed P&T's primary and secondary charge. The committee members are charged with recommending drugs to be preferred, acting as a sounding board for agency policies related to medications, ensure SC DHHS' drug coverage policies are consistent with best medical evidence and avoid cost discussion with a focus on relative effectiveness and safety. Additionally, Bryan advised the group that State law requires four meetings per year. Going forward, there will be two meetings in May, one in August and one in November.

Lisa presented new drugs to market. Bryan also discussed the following policy changes: SCRIPTS mandate (April 1, 2016), Behavioral Health Carve-In (July 1, 2016), MCO contract extension (July 1, 2016), the Outpatient Drug Final Rule and Check-up moving back to Family Planning.

## 7. Resolved Items

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

Classes for Re-Review

Otic Antibiotics

Antibiotics, Topical

Antivirals, Topical

Hypoglycemics, Metformin

Acne Agents, Topical (Retinoids)

Acne Agents, Topical (Sodium Sulfacetamide/Sulfur)

Epinephrine, Injectable

Classes for Review

**Emergency Treatment: Opioid Overdose** 

## 8. Closing Comments

The next meeting will be held on Wednesday, May 18, 2016, at 4:00 p.m.

## 9. Adjournment

The meeting adjourned at 5:30 p.m.